InMed Pharmaceuticals Inc. (MTRI) stock
MTRINasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as INM
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 4/30
$15.29−2.21 (-12.66%)
Close on Nov 18, 2026Market cap $83.97MP/E –Yield –
InMed Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
InMed Pharmaceuticals's operating income for the twelve months ending Sep 30, 2023 was -$6.97M. For fiscal 2023 it was -$7.95M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Jun 30, 2023 | -$7.95M | – |
| FY2022 | Jun 30, 2022 | -$18.60M | – |
| FY2021 | Jun 30, 2021 | -$10.20M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | -$2.54M | – |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | -$338.39K | – |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | -$2.00M | – |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | -$2.10M | – |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | -$3.51M | – |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | -$7.87M | – |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | -$3.48M | – |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | -$4.28M | – |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | -$2.97M | – |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | -$3.26M | – |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | -$3.10M | – |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | -$2.24M | – |
See a number that looks wrong?